Boston, MA -- (SBWIRE) -- 02/16/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H2 2016, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Get More Details on this Report and a Full Table of Contents at Melanoma - Pipeline Review, H2 2016

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 92, 111, 3, 208, 24 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 14, 10, 62 and 12 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).

-The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.

Companies Mentioned in this Report: 4SC AG, AB Science SA, AbbVie Inc, Abivax SA, Acetylon Pharmaceuticals Inc, Adamis Pharmaceuticals Corp, Adaptimmune Therapeutics Plc, Adicet Bio Inc, Aduro BioTech Inc, Advanced Cancer Therapeutics, Advaxis Inc, Aeterna Zentaris Inc, Affichem SA, Agalimmune Ltd, Agenus Inc, Agilvax Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alethia Biotherapeutics Inc, Altor BioScience Corp, Amgen Inc, Anavex Life Sciences Corp, Angimmune LLC, Antibe Therapeutics Inc, Antigen Express Inc, APEIRON Biologics AG, Apexigen Inc, Aphios Corp, APO-T BV, Apogenix GmbH, Aposense Ltd, Aptose Biosciences Inc, Arisaph Pharmaceuticals Inc, ARMO Biosciences Inc, Array BioPharma Inc, Asana BioSciences LLC, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, Azaya Therapeutics Inc, Basilea Pharmaceutica Ltd, Batu Biologics Inc, Bayer AG, BeiGene Ltd, Beijing Kawin Technology Share-Holding Co Ltd, Bellicum Pharmaceuticals Inc, BerGenBio AS, Bio-Cancer Treatment International Ltd, Biocad, Biogazelle NV, Biogenomics Ltd, BioLineRx Ltd, Bioncotech Therapeutics SL, Bionomics Ltd, BioNTech AG, Biothera Pharmaceutical Inc, Biovista Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences Inc, Can-Fite BioPharma Ltd, CCRP Therapeutics GmbH, Cellceutix Corp, Celldex Therapeutics Inc, Celprogen Inc, Celyad SA, Checkmate Pharmaceuticals Inc, Chipscreen Biosciences Ltd, Chugai Pharmaceutical Co Ltd, Cipher Pharmaceuticals Inc, Cornerstone Pharmaceuticals Inc, Cortice Biosciences Inc, Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, Cytune Pharma SAS, CyTuVax BV, CZ BioMed Corp, Daiichi Sankyo Company Ltd, Deciphera Pharmaceuticals LLC, DEKK-TEC Inc, Dicerna Pharmaceuticals Inc, DormaTarg Inc, Dynavax Technologies Corp, Eisai Co Ltd, Eli Lilly and Company, Elsalys Biotech SAS, Ensol Biosciences Inc, EntreChem SL, eTheRNA Immunotherapies NV, Evelo Therapeutics Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faes Farma SA, Five Prime Therapeutics Inc, Formune SL, Galapagos NV, Galectin Therapeutics Inc, Genelux Corp, Genocea Biosciences Inc, Genzyme Corp, GlaxoSmithKline Plc, Gradalis Inc, GreenPeptide Co Ltd, Hadasit Medical Research Services & Development Ltd, HanAll Biopharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, Heat Biologics Inc, HEC Pharm Co Ltd, Hemispherx Biopharma Inc, Histogen Inc, Horizon Pharma Plc, Humorigin Biotechnology Corp, Idera Pharmaceuticals Inc, Ignyta Inc, Immodulon Therapeutics Ltd, Immune Design Corp, Immune Response BioPharma Inc, ImmunGene Inc, Immunocore Ltd, ImmunoGen Inc, Immupharma Plc, ImmuRx Inc, IMPACT Therapeutics Inc, Imugene Ltd, Incuron LLC, Incyte Corp, Infinity Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, IO Biotech ApS, JHL Biotech Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, KaloBios Pharmaceuticals Inc, Kancera AB, Karyopharm Therapeutics Inc, Kite Pharma Inc, Kura Oncology Inc, Lentigen Technology Inc, Life Science Pharmaceuticals Inc, Lindis Biotech GmbH, Lion Biotechnologies Inc, Lipotek Pty Ltd, Loxo Oncology, Inc., Lupin Ltd, Lytix Biopharma AS, MacroGenics Inc, Magnus Life Ltd, MaxiVAX SA, MediaPharma srl, Medicenna Therapeutics Inc, MedImmune LLC, Medisyn Technologies Inc, Medivation Inc, MELEMA Pharma GmbH, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, Modulate Therapeutics Inc, Molecular Templates Inc, Moleculin Biotech Inc, Morphotek Inc, Nektar Therapeutics, Neonc Technologies Inc, Nerviano Medical Sciences Srl, Neumedicines Inc, NewLink Genetics Corp, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, Novogen Ltd, Omeros Corp, Oncology Research International Ltd, Oncolys BioPharma Inc, Oncolytics Biotech Inc, OncoNOx ApS, OncoSec Medical Inc, OncoTartis Inc, Oncovir Inc, Onxeo SA, Orega Biotech SAS, OSE Immunotherapeutics, Pacific Northwest Biotechnology LLC, Patrys Ltd, PepTx Inc, PepVax Inc, Pfizer Inc, Pharmicell Co Ltd, Pharminox Ltd, Pharmis Biofarmaceutica Lda, Philogen SpA, PinCell srl, Pivotal BioSciences Inc, Plexxikon Inc, Polaris Pharmaceuticals Inc, Polyplus-Transfection SA, Prima BioMed Ltd, Propanc Health Group Corp, Provectus Biopharmaceuticals Inc, Provenance Biopharmaceuticals Corp, Qu Biologics Inc, Reata Pharmaceuticals Inc, Recepta Biopharma SA, Recombio SL, Rexahn Pharmaceuticals Inc, Rgenix Inc, Rigontec GmbH, RXi Pharmaceuticals Corp, Sapvax, SATT North SAS, Scancell Holdings Plc, SilaGene Inc, Sillajen Biotherapeutics, SolaranRx Inc, Sorrento Therapeutics Inc, Spotlight Innovation Inc, Sumitomo Dainippon Pharma Co Ltd, Sun Pharma Advanced Research Company Ltd, Susavion Biosciences Inc, SuviCa Inc, Syndax Pharmaceuticals Inc, Taiga Biotechnologies Inc, TaiRx Inc, Taiwan Liposome Company Ltd, Takara Bio Inc, Takeda Pharmaceutical Company Ltd, Takis Srl, Tara Immuno-Oncology Therapeutics LLC, Targovax ASA, TC BioPharm Ltd, TetraLogic Pharmaceuticals, Theravectys SA, Tikcro Technologies Ltd, TILT Biotherapeutics Ltd, Tiltan Pharma Ltd, Tocagen Inc, TREAT U SA, TVAX Biomedical Inc, TyrNovo Ltd, UbiVac LLC, Ultimovacs AS, UNC Health Care, Vaccibody AS, Vascular Biogenics Ltd, Vault Pharma Inc, Vaxenta Biotechnologies, Vichem Chemie Research Ltd, Viralytics Ltd, ViraTherapeutics GmbH, Virttu Biologics Ltd, VLP Therapeutics LLC, WntResearch AB, X4 Pharmaceuticals Inc, ZIOPHARM Oncology Inc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:
-Metastatic Melanoma - Pipeline Review, H2 2016
-Uveal Melanoma - Pipeline Review, H2 2016
-Uveal Melanoma - Pipeline Review, H2 2016
-Metastatic Uveal Melanoma - Pipeline Review, H2 2016
-Melanocyte Protein PMEL - Pipeline Review, H2 2016